
Cumberland Pharmaceuticals invests $4 million in Talicia
Specialty pharmaceuticals company Cumberland Pharmaceuticals has invested $4 million in Talicia, the global product developed by biopharmaceutical company RedHill Biopharma. Talicia is the number one branded US gastroenterologist-prescribed H. pylori therapy, listed as a first-line H. pylori therapy in American College of Gastroenterology Clinical Guidelines. It remains the only FDA-approved all-in-one, low-dose rifabutin-based H. pylori therapy… Read More

